Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD
Congressional District Code:
Biomedical Laboratory R&D
July 2021 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
Acute myeloid leukemia (AML), the common type of acute leukemia in adults, is an important health concern for Veterans due to its high incidence and frequent poor response to treatment. Internal tandem duplication (ITD) of the fms-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase is present in AML cells of 30% of patients and is associated with poor treatment outcomes. FLT3 inhibitors have activity, but responses are limited and transient, with rapid development of resistance occurring by d...